| ≤65 years (n = 116) | 66-70 years (n = 144) | 71-75 years (n = 158) | >75 years (n = 110) | significant difference |
---|---|---|---|---|---|
patient age, years mean ± SD; median | 62 ± 4; 63 | 68 ± 2; 68 | 73 ± 2; 73 | 78 ± 2; 77 | all comparisons (p < 0.01) |
prostate volume, cc mean ± SD; median | 42 ± 20; 35 | 44 ± 20; 39 | 45 ± 23; 40 | 46 ± 21; 42 | - |
PSA<10 ng/mL, n (%) | 66 (57) | 93 (65) | 95 (60) | 55 (50) | 66-70 vs. >75 years (p < 0.05) |
biopsy Gleason score <7; n (%) | 72 (62) | 90 (63) | 98 (62) | 55 (50) | 66-70 vs. >75 years (p < 0.05) |
prior hormonal therapy; n (%) | 46 (40) | 50 (35) | 55 (35) | 41 (37) | - |
comorbidities; n (%) | 56 (48) | 95 (66) | 108 (68) | 69 (63) | ≤65 vs. 66-70/71-75/>75 years (p < 0.05) |
hypertension; n (%) | 24 (21) | 44 (31) | 53 (34) | 27 (25) | ≤65 vs. 71-75 years (p < 0.05) |
coronary heart disease; n (%) | 17 (15) | 29 (20) | 43 (27) | 30 (27) | ≤65 vs. 71-75/>75 years (p < 0.05) |
diabetes; n (%) | 13 (11) | 16 (11) | 17 (11) | 16 (15) | - |
COPD; n (%) | 7 (6) | 13 (9) | 17 (11) | 12 (11) | - |
CCI<5/5/>5; n (%) | 86/17/13 (74/15/11) | 69/49/26 (48/34/18) | 0/85/73 (0/54/46) | 0/47/63 (0/43/57) | for all (p < 0.01), with exception 71-75 vs. >75 |